Compare Docusign Inc (DOCU) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs 22nd Century Group Inc — how do they compare? Docusign Inc trades at $59.42 (market cap $11.33B), while 22nd Century Group Inc trades at $4.33 (market cap $1.52M). The key difference: Docusign Inc is far larger — about 7453.9× 22nd Century Group Inc's market cap, and Docusign Inc is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals.
| DOCU | XXII | |
|---|---|---|
Market Cap | $11.33B | $1.52M |
Sector | Technology | Technology |
52-Week High | $85.01 | $801.00 |
52-Week Low | $41.75 | $3.72 |
Enterprise Value | $10.70B | -$6.71M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $57.82, down 3.05% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.09 exceeding the $0.994 estimate. Revenue growth remains steady, reaching $2.98B in 2025, while profitability improved significantly with a net income margin of 35.87%. Recent news highlights institutional trading activity and positive analyst coverage on growth prospects.
The outlook for DOCU is mixed; fundamentals show robust revenue growth and expanding margins, but valuation multiples like a P/E of 38.53 suggest premium pricing. Key risks include competitive pressures in e-signature software and reliance on subscription revenue. Analyst consensus is cautious with a hold-heavy rating, though the $55.40 price target implies limited upside from current levels.
XXII trades at $4.38, up 0.69% with neutral technical signals. The company shows concerning fundamentals with negative profit margins (-65.76% net income margin) and ROE of -130.19%, though valuation ratios appear low (P/S 0.03, P/B 0.07). Recent corporate actions include a 20:1 reverse stock split in June 2026. Analyst sentiment remains positive with 75% buy ratings, while the company expands VLN® product distribution in key markets like California and New York.
The outlook remains speculative given persistent losses despite revenue generation. Investment opportunity lies in successful execution of reduced-nicotine cigarette expansion and FDA regulatory progress. Key risks include continued cash burn, competitive pressures, and dependency on regulatory approvals for growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
